Comment
. 2007 Sep;105(3):883-4; author reply 884.
doi: 10.1213/01.ane.0000269685.86443.a8.
Sugammadex-rocuronium dosing
- PMID: 17717263
- DOI: 10.1213/01.ane.0000269685.86443.a8
Item in Clipboard
Comment
Sugammadex-rocuronium dosing
Anesth Analg.
2007 Sep.
No abstract available
Comment on
-
A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.Anesth Analg. 2007 Mar;104(3):555-62. doi: 10.1213/01.ane.0000260135.46070.c3. Anesth Analg. 2007. PMID: 17312208 Clinical Trial.
Similar articles
-
Rocuronium and sugammadex in myotonic dystrophy.Anaesth Intensive Care. 2010 Sep;38(5):959-60. Anaesth Intensive Care. 2010. PMID: 20865895 No abstract available.
-
Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex.Can J Anaesth. 2008 Feb;55(2):124-5; author reply 125-6. doi: 10.1007/BF03016324. Can J Anaesth. 2008. PMID: 18245072 No abstract available.
-
[Sugammadex use experience in pediatric oncology].Anesteziol Reanimatol. 2013 Jan-Feb;(1):34-7. Anesteziol Reanimatol. 2013. PMID: 23808251 Russian.
-
[Possible clinical potential in reverting muscular block with sugammadex in anaesthesia and surgery].Ugeskr Laeger. 2013 Feb 11;175(7):428-32. Ugeskr Laeger. 2013. PMID: 23402253 Review. Danish.
-
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.J Clin Anesth. 2016 Dec;35:1-12. doi: 10.1016/j.jclinane.2016.06.018. Epub 2016 Aug 4. J Clin Anesth. 2016. PMID: 27871504 Review.
Cited by
-
[Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].Anaesthesist. 2009 Jan;58(1):66-80. doi: 10.1007/s00101-008-1455-2. Anaesthesist. 2009. PMID: 19082568 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
